Clinical trial
Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
NCT05406999
Study timeline
Study start (actual)2020-02-01Date precision: day
Registry last updated2022-08-16
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Neoadjuvant Therapyunresolved
High Risk Prostate Cancerunresolved
Locally Advanced Prostate Cancerunresolved
Intense Endocrine Therapyunresolved
Interventions
ADTDRUG
Abiraterone AcetateDRUG · verified · RxNorm: abiraterone acetate
EnzalutamideDRUG · verified · RxNorm: enzalutamide
ApalutamideDRUG · verified · RxNorm: apalutamide
DarotamideDRUG
RezvilutamideDRUG
PARP inhibitorDRUG
Robot-assisted radical prostatectomyPROCEDURE
Sponsors & collaborators
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05406999 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.